Boston Therapeutics, Inc.
BTHE · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $9 | $17 |
| Gross Profit | $0 | $0 | -$9 | -$16 |
| % Margin | – | – | – | -1,434.8% |
| R&D Expenses | $971,127 | $490 | $3 | $55 |
| G&A Expenses | $0 | $831 | $575 | $203 |
| SG&A Expenses | $784,556 | $831 | $575 | $203 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,755,683 | $1,320 | $578 | $258 |
| Operating Income | -$1,756 | -$1,320 | -$587 | -$273 |
| % Margin | – | – | – | -25,110.7% |
| Other Income/Exp. Net | -$2,472,533 | -$2,259 | -$13,444 | -$82 |
| Pre-Tax Income | -$2,474,289 | -$3,579 | -$14,030 | -$356 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,474,289 | -$3,579 | -$14,030 | -$356 |
| % Margin | – | – | – | -32,663.7% |
| EPS | -2.7 | -0.004 | -0.02 | -0.003 |
| % Growth | -69,130.8% | 80.8% | -534.4% | – |
| EPS Diluted | -2.7 | -0.004 | -0.02 | -0.003 |
| Weighted Avg Shares Out | 916,915 | 916,915 | 690,049 | 111,131 |
| Weighted Avg Shares Out Dil | 916,915 | 916,915 | 690,049 | 111,131 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$718,605 | $328 | $22 | $115 |
| Depreciation & Amortization | $42 | $17 | -$13,422 | $33 |
| EBITDA | -$3,192,852 | -$3,234 | -$14,009 | -$208 |
| % Margin | – | – | – | -19,104% |